Wiktor Kowalczyk

Wiktor Kowalczyk

Auto-generated profile, based on publicly available information

Wiktor Kowalczyk

Copernicus PL Sp. z o.o., St. Adalbert Hospital, Aleja Jana Pawła II 50, 80-462 Gdańsk, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
WKWiktor Kowalczyk
Wiktor Kowalczyk
WOWeronika Olech
Weronika Olech
JKJulia KęPska
Julia KęPska
ASAneta Synakiewicz
Aneta Synakiewicz
NLNatalia Lewińska
Natalia Lewińska
NBNicole Bulińska
Nicole Bulińska
Background. Migraine is a complex neurobiological disorder associated with the activation of the trigeminovascular system. Many new publications about new drugs appear, but not all of them assign the drug to the most appropriate group of patients.Materials and Methods. We used PubMed to search for studies published between 2016 and 2026. We searched meta-analyses, original clinical trials, and clinical guidelines. Studies were assessed for efficacy and side effects of individual therapeutic substances. Aim. The aim is to compare pharmacological methods used in the acute treatment of migraine attacks (NSAIDs, triptans, ditans, gepants, and opioids), with a particular emphasis on safety profiles and target patient populations. Results. Modern NSAID formulations optimize absorption speed and treatment tolerability. Triptans are the gold standard, but their bothersome side effects frequently lead to therapy discontinuation. An effective alternative for patients with cardiovascular contraindications or insufficient response to triptans (TIR) are new drugs – ditans (lasmiditan) and gepants (e.g. ubrogepant). Lasmiditan demonstrates high efficacy, although, unfortunately, it causes central nervous system symptoms (including dizziness). Gepants, which block the CGRP receptor, offer a favorable tolerability profile and consequently result in high patient satisfaction. Furthermore, the review outlines the issue of opioid use in the pediatric population and emergency departments, bringing out its lack of effectiveness and the associated risk of pain chronification.Conclusions. New drug classes, such as gepants and ditans, are changing migraine management by bypassing the vascular component and enabling better therapy personalization.

9 June 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
JKJulia KęPska
Julia KęPska
WKWiktor Kowalczyk
Wiktor Kowalczyk
WOWeronika Olech
Weronika Olech
ASAneta Synakiewicz
Aneta Synakiewicz
NLNatalia Lewińska
Natalia Lewińska
KWKamil Wójcik
Kamil Wójcik
Background: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder frequently treated with stimulant and non-stimulant medications. Due to the increasing use of ADHD pharmacotherapy, concerns regarding cardiovascular safety have become increasingly important. Aim: This review aimed to summarize current evidence regarding the cardiovascular effects of medications used in ADHD. Materials and Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science databases. Studies published between 2015 and 2026 evaluating cardiovascular outcomes associated with ADHD medications were included. Results: Current evidence indicates that ADHD medications may cause modest increases in blood pressure and heart rate, mainly due to enhanced sympathetic nervous system activity. Stimulants demonstrated stronger hemodynamic effects, whereas α2-adrenergic agonists were associated with reductions in blood pressure and heart rate. Most studies did not demonstrate a substantial increase in serious cardiovascular events in the general ADHD population. However, higher cardiovascular risk may occur in patients with pre-existing cardiovascular disease, arrhythmias, or long-term cumulative medication exposure. Conclusions: ADHD medications are generally associated with mild and manageable cardiovascular effects in most patients. Nevertheless, individualized cardiovascular risk assessment and regular monitoring remain important, particularly in high-risk populations.

14 July 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
ADArina Drobashko
Arina Drobashko
JKJulia KęPska
Julia KęPska
APAleksandra Iga Pociej
Aleksandra Iga Pociej
NMNikola Murawska
Nikola Murawska
KWKamil Wójcik
Kamil Wójcik
NLNatalia Lewińska
Natalia Lewińska
Introduction. Breast reconstruction after mastectomy represents an important component of breast cancer treatment, modifying not only aesthetic outcomes as well as quality of life, body image, and psychosocial functioning. The most commonly used methods include reconstruction with autologous tissue and reconstruction with artificial materials, mainly implants; however, the optimal reconstructive technique remains a matter of debate. Aim. The aim of this review was to analyze and compare the quality of life and patient satisfaction after autologous and implant-based breast reconstruction, using available clinical studies, cohort studies, and meta-analyses. Methods. A systematic literature review was performed using publications that used specific types of questionnaires, which can serve as objective scales for assessing quality of life after different types of breast reconstruction. Among these scales, the following can be mentioned: BREAST-Q, BODY-Q, SF-36, and HADS. Results. Most of the analyzed studies reported higher quality-of-life and satisfaction scores after autologous reconstruction, particularly in the domains of satisfaction with breasts, satisfaction with outcome, psychosocial well-being, and sexual well-being. Results concerning physical well-being were less consistent. Implant-based reconstruction was associated with a shorter and less burdensome treatment course; however, its long-term results may be limited by implant-related complications and the effects of radiotherapy. Conclusions. Autologous breast reconstruction appears to provide more favorable quality-of-life and satisfaction outcomes than implant-based reconstruction. Nevertheless, the choice of reconstructive method should be individualized and should consider the patient’s clinical status, planned oncological treatment, risk of complications, and personal preferences.

30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
NMNikola Murawska
Nikola Murawska
APAleksandra Iga Pociej
Aleksandra Iga Pociej
NLNatalia Lewińska
Natalia Lewińska
ASAneta Synakiewicz
Aneta Synakiewicz
WOWeronika Olech
Weronika Olech
KBKarina Brzózka
Karina Brzózka
Background and Objectives: Altitude training is widely used by endurance athletes to improve aerobic performance through haematological and non-haematological adaptations. Optimal training models and determinants of individual response remain debated. The aim of this review is to summarise current evidence on the physiological adaptations, training models, and clinical risks associated with altitude training in adult endurance athletes. Methods: Literature from 2019 to 2025 was reviewed using PubMed/MEDLINE, Google Scholar, Scopus, and Web of Science. A total of 42 sources were included. Key Findings: Altitude training at ≥2000 m for ≥3 weeks consistently increases haemoglobin mass and haemoglobin concentration, an effect replicated across multiple randomised trials [1, 6]. Improvements in VO₂max are variable and not always statistically significant [6]. Living at altitude while training at lower elevation has the strongest evidence base among available models [14]. Iron status critically moderates the response: athletes with low pre-camp ferritin show blunted adaptations regardless of altitude dose [7]. Sex differences in hypoxic physiology remain an important and understudied area [8, 19]. Conclusions: Altitude training, when properly implemented, is one of the more reliable tools available to endurance athletes. The data supports its use, but only if iron status is optimized beforehand, protocols are personalized to the individual, and clinical risks are managed carefully. More standardized studies are still required, especially in female athletes.

12 June 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
APAleksandra Iga Pociej
Aleksandra Iga Pociej
ADArina Drobashko
Arina Drobashko
NMNikola Murawska
Nikola Murawska
KWKamil Wójcik
Kamil Wójcik
JKJulia KęPska
Julia KęPska
NLNatalia Lewińska
Natalia Lewińska
Background: Physical activity promotes health and positively modulates the gut microbiota. Evidence suggests a "gut-muscle axis" through which probiotic supplementation may enhance athletic performance. Results across direct performance indicators remain inconclusive due to variations in strains and dosages. Aim: This review aims to evaluate studies on the impact of probiotic supplementation on physical performance. Materials and Methods: A systematic literature search was conducted in PubMed and Scopus databases. The search strategy followed PRISMA guidelines. Studies published between 2021 to 2026 were included based on the PICO framework: healthy adults, oral probiotic intervention, placebo control, and validated physical performance outcomes. Results: The analysis indicates that probiotics significantly improve muscular strength, explosive power, and aerobic capacity, particularly when administered as multi-strain formulations or in synergy with other nutrients. Probiotics also effectively attenuate exercise-induced muscle damage, accelerating the recovery. Single-strain interventions and protocols in elite athletes often showed limited effects. High-dose protocols lasting over 8 weeks were the most beneficial. Conclusions: Probiotic supplementation is an effective strategy to support athletic performance and recovery, with its potential significantly amplified through synbiotic combinations. Mechanisms include increased short-chain fatty acid production and reduced oxidative stress and inflammation. Future research must address current limitations, including the lack of female cohorts, small sample sizes, and the need for standardized postbiotic protocols.

30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KWKami Krzysztof Wójcik
Kami Krzysztof Wójcik
IGIrmina Grygutis
Irmina Grygutis
JKJulia KęPska
Julia KęPska
WOWeronika Olech
Weronika Olech
WKWiktor Kowalczyk
Wiktor Kowalczyk
MDMilena Dziedzina
Milena Dziedzina
Sarcopenia, traditionally associated with aging, has been increasingly recognized in younger populations. Early-onset muscle loss may have significant long-term metabolic and functional consequences. This review aims to summarize current evidence on the epidemiology, pathophysiology, risk factors, and preventive strategies of sarcopenia in young adults. A structured literature search was conducted using the PubMed database, prioritizing studies published between 2010 and 2025, including systematic reviews, meta-analyses, and narrative reviews. Current evidence suggests that the prevalence of sarcopenia in adult populations ranges from approximately 10% to over 20%, although data specific to younger individuals remain limited. In this group, sarcopenia is primarily associated with physical inactivity, inadequate nutrition, obesity, and metabolic dysfunction. Chronic low-grade inflammation and insulin resistance contribute to impaired muscle protein synthesis and increased catabolism, while early impairments in muscle function may remain clinically underrecognized. Resistance training and adequate protein intake remain the most effective preventive strategies, particularly when applied in combination. Early identification of at-risk individuals and targeted lifestyle interventions may play a crucial role in preventing long-term adverse health outcomes. Sarcopenia should therefore not be considered exclusively an age-related condition but rather a multifactorial process that may begin early in adulthood.